Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Xu, Jian-Ming; Zhang, Yun; Jia, Ru; Yue, Chunyan; Chang, Lianpeng; Liu, Rongrui; Zhang, Gairong; Zhao, Chuanhua; Zhang, Yaoyue; Chen, Chunxia; Wang, Yan; Yi, Xin; Hu, Zhiyuan; Zou, Jianjun; Wang, Quanren

doi:10.1158/1078-0432.ccr-18-2484

Public

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

Published in Clinical Cancer Research • Oct 22, 2018

Authors:

Jian-Ming Xu

Yun Zhang

Ru Jia

Abstract

PURPOSE: This study assessed the safety and efficacy of SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) as combination therapy in patients with advanced hepatocellular carcinoma (HCC), gastric, or esophagogastric junction cancer (GC/EGJC). PATIENTS AND METHODS: = 28) received apatinib ...

Subject

Apatinib

Medicine

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!